why choose us

Clinical Trials Search

Showing 16,140 of 132,656 result(s)
Dose Escalation;Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Status: Completed

Condition: Chronic Lymphocytic Leukemia

Interventions: Fludarabine is an antimetabolite given prior to lymphodepletion.

Date: 2023-01-12

Sleep, Diet, Exercise and Older Persons

Status: COMPLETED

Condition: Cognitive Change

Interventions: three times per week; 45 minutes per session; 12-weeks

Date: 2023-01-12

Tourette Discrimination (TD) Stigma Scale

Status: Completed

Condition: Tourette Syndrome

Interventions:

Date: 2023-01-12

Novel Coronavirus Infection and Reproductive Function

Status: Completed

Condition: COVID-19 Infection

Interventions: no intervention

Date: 2023-01-12

Tranexamic Acid as an Intervention in Abruptio Placenta

Status: COMPLETED

Condition: Vaginal Bleeding

Interventions: This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenou

Date: 2023-01-12

Evaluation of Broadband Light Treatment for Pigmented Skin Lesions

Status: Completed

Condition: Pigmentation

Interventions: Broadband Light treatment using standard protocol

Date: 2023-01-12

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

Status: Completed

Condition: Glioblastoma Multiforme

Interventions: The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat

Date: 2023-01-12

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Status: Completed

Condition: Metastatic Solid Tumor

Interventions: Given orally

Date: 2023-01-12

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Status: Completed

Condition: Nonsmall Cell Lung Cancer Stage III

Interventions: Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes.
Each treatment is called a cycle and lasts for four we

Date: 2023-01-12

IV SafeLock Device Functionality in Emergency Department

Status: COMPLETED

Condition: Intravenous Access

Interventions: Designed to prevent patient access to intravenous lines in the hospital setting.
The device locks with an institution specific key and protects t

Date: 2023-01-12